# Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

> **NCT00006184** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Myeloma Immunoglobulin Idiotype Vaccine
- **DRUG:** Bortezomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Cyclosporine
- **DRUG:** Doxorubicin hydrochloride
- **DRUG:** Etoposide
- **DRUG:** Fludarabine phosphate
- **DRUG:** Prednisone
- **DRUG:** Vincristine Sulfate
- **DRUG:** Methotrexate
- **BIOLOGICAL:** GMCSF (granulocyte macrophage colony stimulating factor)
- **BIOLOGICAL:** GCSF (granulocyte colony stimulating factor)

## Key facts

- **NCT ID:** NCT00006184
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02-08
- **Primary completion:** 2008-01-12
- **Final completion:** 2008-01-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006184, "Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00006184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*